05:14 EST 16th December 2018 | BioPortfolio

Duvelisib, which is being developed by Infinity Pharmaceutical for the treatment of CLL and small lymphocytic lymphoma (SLL).  CLL occurs when blood stem cells develop into abnormal lymphocytes which do not function properly. These are produced in the bone marrow, preventing the production of normal healthy blood cells, and can accumulate in the lymph nodes and spleen, and enter the  bloodstream. 

The disease generally develops very slowly and it may be months or years before symptoms present themselves. SLL is considered to be a different version of the same condition, the only difference being the location of the cancerous cells. In CLL, these are mainly in the blood and bone marrow, whereas the majority of cancer cells in SLL are found in the lymph nodes and spleen.

Duvelisib is a potent, orally available inhibitor of phosphoinositide-3 kinase delta and phosphoinositide-3 kinase gamma, which are
expressed on white blood cells and involved with cellular functions such as cell proliferation, cell migration, cell differentiation and immunity.
The drug was originally developed by Takeda subsidiary Intellikine, but Infinity acquired worldwide development and commercialization
rights in July 2010. 

Adapted from - Thomson Reuters Cortellis Competitive Intelligence

Quick Search


review and buy Duvelisib market research data and corporate reports here